Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| enVVeno Medical CorpNVNO · Entity 8104 | Director | December 11, 2025 | December 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
enVVeno Medical Corp
Report date December 11, 2025 · Filed December 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.33 · Expires 2035-12-11 | Direct | 135,883 |
Reported balance
After 2025-12-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-11 · Grant · Acquired 135,883 · Balance 135,883 F1: The common stock options were issued to the Reporting Person on December 11, 2025 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year. |
Filing footnotes · ownership attribution and instrument terms
F1: The common stock options were issued to the Reporting Person on December 11, 2025 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2025 Filed Dec 15, 2025 20:40 UTC | enVVeno Medical Corp NVNO · Entity 8104 | GrantStock Options · Derivative | 135,883 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001493152-25-027832 · ownership.xml · derivative · entry 1 Jenusaitis Matthew · CIK 0001357864 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,883 Underlying: Common Stock · 135,883 shares Expires 2035-12-11 F1 · derivative.exercise_date: The common stock options were issued to the Reporting Person on December 11, 2025 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 06:03 UTC | enVVeno Medical Corp NVNO · Entity 8104 | PurchaseCommon Stock | 9,620 | $2.53 | $24,338.60 |
DisclosureSEC source: 0001493152-24-051172 · ownership.xml · nonDerivative · entry 1 Jenusaitis Matthew · CIK 0001357864 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,545 Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 20:33 UTC | enVVeno Medical Corp NVNO · Entity 8104 | GrantStock Options · Derivative | 19,752 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001493152-24-051145 · ownership.xml · derivative · entry 1 Jenusaitis Matthew · CIK 0001357864 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,752 Underlying: Common Stock · 19,752 shares Expires 2034-12-18 F1 · derivative.exercise_date: The common stock options were issued to the Reporting Person on December 18, 2024 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2025 calendar year. Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 17:06 UTC | enVVeno Medical Corp NVNO · Entity 8104 | GrantStock Options · Derivative | 13,856 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001493152-23-044059 · ownership.xml · derivative · entry 1 Jenusaitis Matthew · CIK 0001357864 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,856 Underlying: Common Stock · 13,856 shares Expires 2033-12-05 F1 · derivative.exercise_date: The common stock options were issued to the Reporting Person on December 5, 2023 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2024 calendar year. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 16:30 UTC | enVVeno Medical Corp NVNO · Entity 8104 | GrantStock Options · Derivative | 8,403 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001493152-22-034312 · ownership.xml · derivative · entry 1 Jenusaitis Matthew · CIK 0001357864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,403 Underlying: Common Stock · 8,403 shares Expires 2032-11-30 F1 · derivative.exercise_date: The common stock options were issued to the Reporting Person on November 30, 2022 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2023 calendar year. Read SEC document |
| September 13, 2022 Filed Sep 16, 2022 16:05 UTC | enVVeno Medical Corp NVNO · Entity 8104 | Exercise / conversionRestricted Stock Units · Derivative | 1,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-026070 · ownership.xml · derivative · entry 2 Jenusaitis Matthew · CIK 0001357864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,041 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") converts into one share of common stock of enVVeno Medical Corporation. F2 · derivative.exercise_date: On September 13, 2019, the reporting person was granted 3,125 RSUs (78,125 RSUs pre one-for-twenty five (1:25) reverse stock split that was effected in November 2020), subject to vesting and settlement as described in the person's Form 4, as filed on October 10, 2020. The vesting and settlement of the RSUs occurred in September 2020, 2021 and 2022. F2 · derivative.expiration_date: On September 13, 2019, the reporting person was granted 3,125 RSUs (78,125 RSUs pre one-for-twenty five (1:25) reverse stock split that was effected in November 2020), subject to vesting and settlement as described in the person's Form 4, as filed on October 10, 2020. The vesting and settlement of the RSUs occurred in September 2020, 2021 and 2022. Read SEC document |
| September 13, 2022 Filed Sep 16, 2022 16:05 UTC | enVVeno Medical Corp NVNO · Entity 8104 | Exercise / conversionCommon Stock | 1,041 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-026070 · ownership.xml · nonDerivative · entry 1 Jenusaitis Matthew · CIK 0001357864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converts into one share of common stock of enVVeno Medical Corporation. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 16:05 UTC | enVVeno Medical Corp NVNO · Entity 8104 | GrantStock Options · Derivative | 7,211 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001493152-21-030303 · ownership.xml · derivative · entry 1 Jenusaitis Matthew · CIK 0001357864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,211 Underlying: Common Stock · 7,211 shares Expires 2031-11-30 F1 · derivative.exercise_date: The common stock options were issued to the Reporting Person on November 30, 2021 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2022 calendar year. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 21:50 UTC | enVVeno Medical Corp HIJI · Entity 8104 | Exercise / conversionRestricted Stock Units · Derivative | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-022863 · ownership.xml · derivative · entry 2 Jenusaitis Matthew · CIK 0001357864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,084 Underlying: Common Stock · 1,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") converts into one share of common stock of Hancock Jaffe Laboratories, Inc. F2 · derivative.exercise_date: On September 13, 2019, the reporting person was granted 3,125 RSUs (78,125 RSUs pre one-for-twenty five (1:25) reverse stock split that was effected in November 2020), subject to vesting and settlement as described in the person's Form 4, as filed on October 10, 2020. The vesting and settlement of 1,042 RSUs occurred on September 13, 2021 F2 · derivative.expiration_date: On September 13, 2019, the reporting person was granted 3,125 RSUs (78,125 RSUs pre one-for-twenty five (1:25) reverse stock split that was effected in November 2020), subject to vesting and settlement as described in the person's Form 4, as filed on October 10, 2020. The vesting and settlement of 1,042 RSUs occurred on September 13, 2021 Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 21:50 UTC | enVVeno Medical Corp HIJI · Entity 8104 | Exercise / conversionCommon Stock | 1,042 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-022863 · ownership.xml · nonDerivative · entry 1 Jenusaitis Matthew · CIK 0001357864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converts into one share of common stock of Hancock Jaffe Laboratories, Inc. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 15:19 UTC | enVVeno Medical Corp HJLI · Entity 8104 | PurchaseCommon Stock, $$0.00001 par value | 1,300 | $7.70 | $10,010.00 |
DisclosureSEC source: 0001493152-21-021444 · ownership.xml · nonDerivative · entry 1 Jenusaitis Matthew · CIK 0001357864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,842 F1 · shares: On August 25, 2021, the reporting person purchased 1,300 shares of common stock in the public market at $7.70 per share. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:58 UTC | enVVeno Medical Corp HJLI · Entity 8104 | GrantStock Option · Derivative | 5,673 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001493152-21-004534 · ownership.xml · derivative · entry 1 Jenusaitis Matthew · CIK 0001357864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,673 Underlying: Common Stock · 5,673 shares Expires 2031-02-18 F1 · security: The stock option was granted pursuant to the registrant's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan").. F2 · derivative.exercise_date: The common stock options were issued to the reporting person as part of the annual board compensation package for 2021. The award is subject to time-based vesting and will vest in equal quarterly portions over the remainder of the 2021 calendar year. Read SEC document |
| July 18, 2020 Filed Oct 21, 2020 16:05 UTC | enVVeno Medical Corp HJLI · Entity 8104 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001493152-20-019736 · ownership.xml · derivative · entry 4 Jenusaitis Matthew · CIK 0001357864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-07-18 F4 · derivative.exercise_date: The common stock options were issued to the Reporting Person pursuant to the Plan on July 18, 2020 as part of the annual board compensation package for 2020. The award is subject to time-based vesting and will vest in equal quarterly portions over the remainder of the 2020 calendar year. Read SEC document |
| July 18, 2020 Filed Oct 21, 2020 16:05 UTC | enVVeno Medical Corp HJLI · Entity 8104 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-019736 · ownership.xml · nonDerivative · entry 1 Jenusaitis Matthew · CIK 0001357864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Read SEC document |
| September 13, 2019 Filed Oct 21, 2020 16:05 UTC | enVVeno Medical Corp HJLI · Entity 8104 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001493152-20-019736 · ownership.xml · derivative · entry 3 Jenusaitis Matthew · CIK 0001357864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-09-13 F3 · derivative.exercise_date: The common stock options were issued to the Reporting Person on September 13, 2019 in connection with joining the Issuer's board of directors pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly portions over a three (3) year period starting from September 13, 2019. Read SEC document |
| September 13, 2019 Filed Oct 21, 2020 16:05 UTC | enVVeno Medical Corp HJLI · Entity 8104 | GrantRestricted Stock Units · Derivative | 78,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-019736 · ownership.xml · derivative · entry 2 Jenusaitis Matthew · CIK 0001357864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,125 Underlying: Common Stock · 78,125 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each Restricted Stock Unit ("RSU") entitles the Reporting Person to one share of the Issuer's common stock or the cash equivalent, at the discretion of the Issuer. F2 · derivative.exercise_date: The RSU were issued to the Reporting Person on September 13, 2019 in connection with joining the Issuer's board of directors pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan (as amended, the "Plan"). The award is subject to time-based vesting and will vest in equal annual portions on: (i) September 13, 2020; (ii) September 13, 2021; and (iii) September 13, 2022. F2 · derivative.expiration_date: The RSU were issued to the Reporting Person on September 13, 2019 in connection with joining the Issuer's board of directors pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan (as amended, the "Plan"). The award is subject to time-based vesting and will vest in equal annual portions on: (i) September 13, 2020; (ii) September 13, 2021; and (iii) September 13, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.